Attenuation of niacin-induced prostaglandin D₂ generation by omega-3 fatty acids in THP-1 macrophages and Langerhans dendritic cells

References

• MeyersCDKamannaVSKashyapMLNiacin therapy in atherosclerosisCurr Opin Lipidol200415665966515529025
   PubMed Web of Science ®Google Scholar
• CarlsonLANicotinic acid: the broad-spectrum lipid drug. A 50th anniversary reviewJ Intern Med200525829411416018787
   PubMed Web of Science ®Google Scholar
• The Coronary Drug Project Research GroupClofibrate and niacin in coronary heart diseaseJAMA197523143603811088963
   PubMed Web of Science ®Google Scholar
• van GreevenbroekMMVoorhoutWFErkelensDWvan MeerGde BruinTWPalmitic acid and linoleic acid metabolism in Caco-2 cells: different triglyceride synthesis and lipoprotein secretionJ Lipid Res199536113247706938
   PubMed Web of Science ®Google Scholar
• WahlbergGWalldiusGOlssonAGKirsteinPEffects of nicotinic acid on serum cholesterol concentrations of high density lipoprotein subfractions HDL2 and HDL3 in hyperlipoproteinaemiaJ Intern Med199022821511572394966
   PubMed Web of Science ®Google Scholar
• GanjiSHZhangL-HKamannaVSKashyapMLEffect of niacin on lipoproteins and atherosclerosisFuture Lipidol200615549
   Google Scholar
• CapuzziDMGuytonJRMorganJMEfficacy and safety of an extended-release niacin (Niaspan): a long-term studyAm J Cardiol19988212A74U81U discussion 85U–86U
   PubMed Web of Science ®Google Scholar
• BackesJMGibsonCAEffect of lipid-lowering drug therapy on small-dense low-density lipoproteinAnn Pharmacother200539352352615671087
   PubMed Web of Science ®Google Scholar
• ParhoferKGReview of extended-release niacin/laropiprant f ixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemiaVasc Health Risk Manag2009590190820016845
   PubMedGoogle Scholar
• VogtAKassnerUHostalekUSteinhagen-ThiessenEEvaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS studyCurr Med Res Opin200622241742516466614
   PubMed Web of Science ®Google Scholar
• BallantyneCMDavidsonMHMcKenneyJMKellerLHBajorunasDRKarasRHComparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) studyJ Clin Lipidol200822799021291724
   PubMed Web of Science ®Google Scholar
• BallantyneCMDavidsonMHMcKenneyJKellerLHBajorunasDRKarasRHComparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)Am J Cardiol2008101101428143618471454
   PubMed Web of Science ®Google Scholar
• KnoppRHDrug treatment of lipid disordersN Engl J Med1999341749851110441607
   PubMed Web of Science ®Google Scholar
• ShepherdJPackardCJPatschJRGottoAMJrTauntonODEffects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolismJ Clin Invest1979635858867221531
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood InstituteHDL-atherosclerosis treatment study (HATS)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine1999 [updated June 23, 2005]. Available from: http://clinicaltrials.gov/ct2/show/NCT00000553?term=NCT00000553&rank=1. NLM identifier: NCT00000553Accessed February 10, 2012
   Google Scholar
• BrownBGZhaoXQChaitASimvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary diseaseN Engl J Med2001345221583159211757504
   PubMed Web of Science ®Google Scholar
• BodenWEProbstfieldJLAndersonTNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med2011365242255226722085343
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood InstituteNiacin plus statin to prevent vascular eventsClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2005 [updated June 3, 2011]. Available from: http://clinicaltrials.gov/ct2/show?term=NCT00120289&rank=1. NLM identifier: NCT00120289Accessed February 12, 2012
   Google Scholar
• GrayDRMorganTChretienSDKashyapMLEfficacy and safety of controlled-release niacin in dyslipoproteinemic veteransAnn Intern Med199412142522587741833
   PubMed Web of Science ®Google Scholar
• SternRHSpenceJDFreemanDJParbtaniATolerance to nicotinic acid flushingClin Pharmacol Ther199150166701855354
   PubMed Web of Science ®Google Scholar
• NozakiSKiharaSKuboMKamedaKMatsuzawaYTaruiSIncreased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushingInt J Clin Pharmacol Ther Toxicol198725126436473481359
   PubMed Web of Science ®Google Scholar
• MorrowJDParsonsWGIIIRobertsLJIIRelease of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acidProstaglandins19893822632742475889
   PubMed Web of Science ®Google Scholar
• EklundBKaijserLNowakJWennmalmAProstaglandins contribute to the vasodilation induced by nicotinic acidProstaglandins1979176821830504690
   PubMed Web of Science ®Google Scholar
• Maciejewski-LenoirDRichmanJGHakakYGaidarovIBehanDPConnollyDTLangerhans cells release prostaglandin D2 in response to nicotinic acidJ Invest Dermatol2006126122637264617008871
   PubMed Web of Science ®Google Scholar
• BenyoZGilleABennettCLClausenBEOffermannsSNicotinic acid-induced flushing is mediated by activation of epidermal langerhans cellsMol Pharmacol20067061844184917008386
   PubMed Web of Science ®Google Scholar
• LorenzenAStannekCBurmeisterAKalvinshISchwabeUG protein-coupled receptor for nicotinic acid in mouse macrophagesBiochem Pharmacol200264464564812167483
   PubMed Web of Science ®Google Scholar
• SogaTKamoharaMTakasakiJMolecular identification of nicotinic acid receptorBiochem Biophys Res Commun2003303136436912646212
   PubMed Web of Science ®Google Scholar
• WiseAFoordSMFraserNJMolecular identification of high and low affinity receptors for nicotinic acidJ Biol Chem2003278119869987412522134
   PubMed Web of Science ®Google Scholar
• BenyoZGilleAKeroJGPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushingJ Clin Invest2005115123634364016322797
   PubMed Web of Science ®Google Scholar
• ChengKWuT-JWuKKAntagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humansProc Natl Acad Sci U S A2006103176682668716617107
   PubMed Web of Science ®Google Scholar
• DaviglusMLStamlerJOrenciaAJFish consumption and the 30-year risk of fatal myocardial infarctionN Engl J Med199733615104610539091800
   PubMed Web of Science ®Google Scholar
• AlbertCMHennekensCHO’DonnellCJFish consumption and risk of sudden cardiac deathJAMA1998279123289424039
   PubMed Web of Science ®Google Scholar
• BangHODyerbergJHjoorneNThe composition of food consumed by Greenland EskimosActa Med Scand19762001–26973961471
   PubMedGoogle Scholar
• Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trialGruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardicoLancet1999354917744745510465168
   PubMed Web of Science ®Google Scholar
• de LorgerilMRenaudSMamelleNMediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart diseaseLancet19943438911145414597911176
   PubMed Web of Science ®Google Scholar
• LeafAAlbertCMJosephsonMPrevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intakeCirculation2005112182762276816267249
   PubMed Web of Science ®Google Scholar
• HarrisWSn-3 fatty acids and lipoproteins: comparison of results from human and animal studiesLipids19963132432528900453
   PubMed Web of Science ®Google Scholar
• MoriTABurkeVPuddeyIBPurified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic menAm J Clin Nutr20007151085109410799369
   PubMed Web of Science ®Google Scholar
• HarrisWSGinsbergHNArunakulNSafety and efficacy of Omacor in severe hypertriglyceridemiaJ Cardiovasc Risk199745–63853919865671
   PubMedGoogle Scholar
• AbeYEl-MasriBKimballKTSoluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesionArterioscler Thromb Vasc Biol19981857237319598830
   PubMed Web of Science ®Google Scholar
• McKenneyJMSicaDPrescription omega-3 fatty acids for the treatment of hypertriglyceridemiaAm J Health Syst Pharm200764659560517353568
   PubMed Web of Science ®Google Scholar
• RheeSGRegulation of phosphoinositide-specific phospholipase CAnn Rev Biochem20017028131211395409
   PubMed Web of Science ®Google Scholar
• LibertyIFRaichelLHazan-EitanZCytosolic phospholipase A2 is responsible for prostaglandin E2 and leukotriene B4 formation in phagocyte-like PLB-985 cells: studies of differentiated cPLA2-deficient PLB-985 cellsJ Leukoc Biol200476117618415123778
   PubMed Web of Science ®Google Scholar
• CapdevilaJHFalckJRHarrisRCCytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenaseJ Lipid Res200041216318110681399
   PubMed Web of Science ®Google Scholar
• SmithWLGaravitoRMDeWittDLProstaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2J Biol Chem19962715233157331608969167
   PubMed Web of Science ®Google Scholar
• StillwellWShaikhSRZerougaMSiddiquiRWassallSRDocosahexaenoic acid affects cell signaling by altering lipid raftsReprod Nutr Dev200545555957916188208
   PubMedGoogle Scholar
• HorejsiVDrbalKCebecauerMGPI-microdomains: a role in signalling via immunoreceptorsImmunol Today199920835636110431155
   PubMedGoogle Scholar
• SiddiquiRAHarveyKAZalogaGPStillwellWModulation of lipid rafts by omega-3 fatty acids in inflammation and cancer: implications for use of lipids during nutrition supportNutr Clin Pract2007221748817242459
   PubMed Web of Science ®Google Scholar
• MeyersCDLiuPKamannaVSKashyapMLNicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flushAtherosclerosis2007192225325816945375
   PubMed Web of Science ®Google Scholar
• FolchJLeesMStanleyGHSA simple method for the isolation and purification of total lipids from animal tissueJ Biol Chem195722649750913428781
   PubMed Web of Science ®Google Scholar
• XuZHarveyKAPavlinaTDutotGZalogaGPSiddiquiRAAn improved method for determining medium- and long-chain FAMEs using gas chromatographyLipids20104519920820082149
   PubMed Web of Science ®Google Scholar
• PapaliodisDBoucherWKempurajDNiacin-induced “flush” involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal modelJ Pharmacol Exp Ther2008327366567218784348
   PubMed Web of Science ®Google Scholar
• KamannaVSGanjiSHKashyapMLThe mechanism and mitigation of niacin-induced flushingInt J Clin Prac200963913691377
   PubMed Web of Science ®Google Scholar
• ChristensenNAAchorRWBergeKGMasonHLNicotinic acid treatment of hypercholesteremia. Comparison of plain and sustained-action preparations and report of two cases of jaundiceJAMA196117754655013693364
   PubMed Web of Science ®Google Scholar
• McKenneyJMProctorJDHarrisSChinchiliVMA comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patientsJAMA199427196726778309029
   PubMed Web of Science ®Google Scholar
• McKenneyJMJonesPHBaysHEComparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)Atherosclerosis2007192243243717239888
   PubMed Web of Science ®Google Scholar
• KashyapMLMcGovernMEBerraKLong-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemiaAm J Cardiol200289667267811897208
   PubMed Web of Science ®Google Scholar
• HunninghakeDBMcGovernMEKorenMA dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatinClin Cardiol200326311211812685616
   PubMed Web of Science ®Google Scholar
• BaysHEBallantyneCWhat’s the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?Curr Opin Lipidol200920646747619779335
   PubMed Web of Science ®Google Scholar
• CefaliEASimmonsPDStanekEJMcGovernMEKisslingCJAspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulationInt J Clin Pharmacol Ther2007452788817323787
   PubMed Web of Science ®Google Scholar
• DunnRTFordMARindoneJPKwiecinskiFALow-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administrationAm J Ther19952747848011850694
   PubMedGoogle Scholar
• ThakkarRBKashyapMLLewinAJKrauseSLJiangPPadleyRJAcetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemiaAm J Cardiovasc Drugs200992697919331435
   PubMed Web of Science ®Google Scholar
• KaijserLEklundBOlssonAGCarlsonLADissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in manMed Biol1979572114117376964
   PubMedGoogle Scholar
• HirafujiMEbiharaTKawaharaFHamaueNEndoTMinamiMInhibition by docosahexaenoic acid of receptor-mediated Ca(2+) influx in rat vascular smooth muscle cells stimulated with 5-hydroxytryptamineEur J Pharmacol2001427319520111567649
   PubMed Web of Science ®Google Scholar
• RinaldiBDi PierroPVitelliMREffects of docosahexaenoic acid on calcium pathway in adult rat cardiomyocytesLife Sci2002719993100412088759
   PubMed Web of Science ®Google Scholar
• HallaqHSmithTWLeafAModulation of dihydropyridine-sensitive calcium channels in heart cells by fish oil fatty acidsProc Natl Acad Sci U S A1992895176017641371883
   PubMed Web of Science ®Google Scholar
• XiaoYFKeQWangSYSingle point mutations affect fatty acid block of human myocardial sodium channel alpha subunit Na+ channelsProc Natl Acad Sci U S A20019863606361111248125
   PubMed Web of Science ®Google Scholar
• SmithWLOmega-3 and omega-6 essential fatty acids and cyclooxygenase pathwaysPaper presented at: Experimental BiologyApr 2006San Fransico, CA
   Google Scholar
• LaneuvilleOBreuerDKXuNFatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)-octadecatrienoic acids from alpha-linolenic acidJ Biol Chem19952703319330193367642610
   PubMed Web of Science ®Google Scholar
• HwangDFatty acids and immune responses – a new perspective in searching for clues to mechanismAnnu Rev Nutr20002043145610940341
   PubMed Web of Science ®Google Scholar
• CoreyEJShihCCashmanJRDocosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesisProc Natl Acad Sci U S A19838012358135846304720
   PubMed Web of Science ®Google Scholar
• OhDYTalukdarSBaeEJGPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effectsCell2011142568769820813258
   PubMed Web of Science ®Google Scholar
• SiddiquiRAHarveyKAZalogaGPModulation of enzymatic activities by n-3 polyunsaturated fatty acids to support cardiovascular healthJ Nutr Biochem20081941744317904342
   PubMed Web of Science ®Google Scholar